title: Intracranial pressure. Monitoring and management.
abstract: Monitoring of ICP from the subarachnoid, intraparenchymal, or ventricular spaces can be accomplished easily and reliably. The risks and benefits of each approach should be considered when choosing the monitoring technique. The goal of ICP management is to prevent herniation and to optimize cerebral perfusion. Even transient episodes of post-traumatic cerebral ischemia due to inadequate CPP can quickly nullify all resuscitative efforts. The provision of sufficient CBF is complicated by the varying degree of disruption of pressure autoregulation commonly resulting from head trauma. Post-injury, there is a need to provide a CPP which is elevated to some extent with respect to that sufficient in uninjured brains. This generally requires a CPP of at least 70 mm Hg, which must be accomplished by maintaining an adequate MAP while controlling ICH. Although ICH can generally be controlled using methods commonly employed, the majority of these techniques have potential complications. Additionally, there is increasing evidence that significant variation exists in the pathologic processes driving ICH in individual patients. Therefore, goals such as the desired CPP and conditions such as the relative contribution of edema, cerebral hypervolemia, and ischemia to ICH should optimally be considered in a patient-specific fashion and allow a targeted approach to therapy.
authors: San Francisco General Hospital, University of California.
authors: E W
authors: EW
authors: Lang
authors: R M
authors: RM
authors: Chesnut
mesh_terms: D001463:Barbiturates / Q000009:adverse effects / Q000627:therapeutic use; D001929:Brain Edema / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D001930:Brain Injuries / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D002408:Catheters, Indwelling; D015170:Cerebrospinal Fluid Pressure / Q000187:drug effects / Q000502:physiology; D003422:Critical Care; D004359:Drug Therapy, Combination; D004867:Equipment Design; D006801:Humans; D008991:Monitoring, Physiologic / Q000295:instrumentation*; D011559:Pseudotumor Cerebri / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D001463:Barbiturates